SABS - SAB Biotherapeutics - Stock Forecast

Coverage Performance Price Targets & Ratings Chart Insider Trading

SABS is currently covered by 2 analysts with an average price target of $15.6. This is a potential upside of $11.21 (255.35%) from yesterday's end of day stock price of $4.39.

SAB Biotherapeutics's activity chart (see below) currently has 3 price targets and 18 ratings on display. The stock rating distribution of SABS is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 31.43% with an average time for these price targets to be met of 114.5 days.

Highest price target for SABS is $25, Lowest price target is $6, average price target is $15.6.

Most recent stock forecast was given by KEAY NAKAE from CHARDAN CAPITAL on 02-Apr-2024. First documented stock forecast 05-Nov-2021.

Best performing analysts who are covering SABS - SAB Biotherapeutics:

Keay Nakae Edward White

Currently out of the existing stock ratings of SABS, 15 are a BUY (100%).

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

25

$20.54 (460.54%)

3

20 days ago

3/7 (42.86%)

$20.71 (482.75%)

157

Buy

6

$1.54 (34.53%)

10

20 days ago

2/10 (20%)

$1.71 (39.86%)

72

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is SABS (SAB Biotherapeutics) average time for price targets to be met?

On average it took 114.5 days on average for the stock forecasts to be realized with a an average price target met ratio 31.43

Which analyst has the current highest performing score on SABS (SAB Biotherapeutics) with a proven track record?

KEAY NAKAE

Which analyst has the current lower performing score on SABS (SAB Biotherapeutics) with a proven track record?

EDWARD WHITE

Which analyst has the most public recommendations on SABS (SAB Biotherapeutics)?

Keay Nakae works at CHARDAN CAPITAL and has 7 price targets and 5 ratings on SABS

Which analyst is the currently most bullish on SABS (SAB Biotherapeutics)?

Keay Nakae with highest potential upside - $20.54

Which analyst is the currently most reserved on SABS (SAB Biotherapeutics)?

Edward White with lowest potential downside - $1.54

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?